Alesia Tietze | Medicinal Chemistry in Cancer | Innovative Research Award

Published on by Global Genetics Award

Innovative Research Award

Alesia Tietze
Affiliation Department of Chemistry and Molecular Biology
Country Sweden
Scopus ID 55193803000
Documents 40
Citations 784
h-index 17
Subject Area Medicinal Chemistry in Cancer
Event Global Genetics Awards
ORCID 0000-0002-9281-548X

Alesia Tietze
Department of Chemistry and Molecular Biology

Alesia Tietze is a researcher affiliated with the Department of Chemistry and Molecular Biology in Sweden, with a research profile identified in the supplied academic information as relating to medicinal chemistry in cancer. The profile is associated with 40 Scopus-indexed documents, 784 citations, and an h-index of 17. These bibliometric indicators provide a quantitative view of research visibility and scholarly impact, while the award assessment itself should be based on the complete research record and independently verified evidence. [3]

Abstract

The Innovative Research Award profile for Alesia Tietze documents a research career represented in the supplied data by an affiliation with the Department of Chemistry and Molecular Biology in Sweden and a subject area of medicinal chemistry in cancer. The associated Scopus record is reported as containing 40 documents, 784 citations, and an h-index of 17. [1] These metrics can be used as supporting indicators of scholarly activity and citation reach, but they do not independently establish the novelty, methodological quality, translational significance, or originality of individual research contributions. The researcher is also associated with an ORCID identifier, providing a persistent identifier for distinguishing the scholarly record. [2]

Keywords

Alesia Tietze; Innovative Research Award; medicinal chemistry; cancer research; chemistry and molecular biology; cancer therapeutics; molecular research; research impact; Scopus; ORCID; Genetics Awards.

Introduction

Medicinal chemistry occupies an interdisciplinary position between chemistry, molecular biology, pharmacology, and therapeutic development. Research in this area may involve the design, synthesis, characterization, optimization, and biological evaluation of compounds intended to address disease-associated molecular targets. In cancer research, medicinal chemistry can intersect with studies of molecular mechanisms, therapeutic targets, biomarkers, drug resistance, and precision-oriented treatment strategies.

Within this broad research environment, academic recognition generally requires consideration of both quantitative and qualitative evidence. Bibliometric indicators such as document counts, citation counts, and h-index values can provide useful measures of scholarly visibility, while publications, methodological contributions, collaborations, and demonstrable scientific outcomes provide additional context. The Genetics Awards program states that submitted research profiles may undergo screening, credential verification, cross-checking of submitted information, and committee review before selection. [3]

Research Profile

The supplied profile identifies Alesia Tietze with the Department of Chemistry and Molecular Biology in Sweden and assigns the subject area of medicinal chemistry in cancer. The reported Scopus information comprises 40 documents, 784 citations, and an h-index of 17. [1] Taken together, these values indicate a documented body of indexed scholarly output and citation activity.

The research profile should be interpreted in relation to the underlying publications rather than as a standalone ranking. Citation indicators can vary according to database coverage, publication type, disciplinary citation practices, author disambiguation, and the date on which the record is consulted. The ORCID identifier supplied for the researcher offers an additional mechanism for connecting scholarly outputs to a persistent researcher identity. [2]

Research Contributions

Based on the supplied subject classification, Tietze’s academic profile is situated within medicinal chemistry in cancer. This field encompasses research that connects chemical science with biological and therapeutic questions relevant to oncology. The precise contribution of an individual researcher should, however, be established from verified publications, research projects, patents, datasets, collaborations, and other primary scholarly evidence rather than inferred solely from a subject-area label.

For an award evaluation, relevant evidence may include the originality of research questions, rigor of experimental or computational methods, reproducibility, significance of findings, contribution to interdisciplinary research, and potential relevance to cancer biology or therapeutic development. The Genetics Awards program identifies research excellence and related scientific contributions among the areas considered within its award framework. [3]

Publications

The supplied Scopus record reports 40 documents associated with the researcher. [1] Because individual publication titles, journals, publication years, authorship positions, and DOI identifiers were not supplied in the source information for this profile, specific publications are not enumerated here. This avoids attributing research findings or bibliographic details that have not been independently established.

For formal award documentation, the publication record can be verified through the researcher’s Scopus author profile and persistent ORCID identifier. Where individual publications are evaluated, DOI metadata should be checked against the publisher or DOI registration record before being included in a nomination dossier.

Research Impact

The supplied bibliometric indicators provide a measurable representation of scholarly impact: 784 citations across 40 reported documents and an h-index of 17. [1] These indicators may support an assessment of sustained research visibility, but they should be interpreted alongside publication quality, contribution to the scientific literature, collaboration, methodological innovation, and the broader significance of the research.

In the context of cancer-focused medicinal chemistry, research impact may also be considered through the extent to which scientific findings contribute to understanding disease mechanisms, identifying therapeutic opportunities, improving molecular tools, or informing subsequent research. Such outcomes require evidence from the underlying scholarly record and should not be inferred solely from citation statistics.

Award Suitability

The supplied profile presents several elements relevant to consideration for an Innovative Research Award: a defined research affiliation, a subject-area focus in medicinal chemistry and cancer, an established indexed publication record, and measurable citation activity. The reported h-index of 17 and 784 citations may serve as supporting bibliometric evidence of scholarly reach. [1]

Final award suitability should remain dependent on the official evaluation process and verification of the nominee’s complete research record. The Genetics Awards program describes a process involving submission screening, verification of credentials, cross-checking of information, committee review, and subsequent selection. [3] Accordingly, the present article should be understood as an academic recognition profile based on the supplied information rather than as an independent declaration of award selection.

Conclusion

Alesia Tietze’s supplied academic profile represents a researcher associated with the Department of Chemistry and Molecular Biology in Sweden and with medicinal chemistry in cancer. The reported Scopus indicators of 40 documents, 784 citations, and an h-index of 17 provide quantitative evidence of an established scholarly record. [1] The associated ORCID identifier further supports persistent scholarly identification. [2]

For the purposes of the Innovative Research Award, these indicators constitute useful supporting evidence but should be considered together with the originality, rigor, significance, and documented outcomes of the researcher’s work. A complete assessment should rely on verified publications and other primary academic evidence in accordance with the award’s stated evaluation procedures. [3]

References

  1. Elsevier. (n.d.). Scopus author details: Alesia Tietze, Author ID 55193803000.

    Scopus.https://www.scopus.com/authid/detail.uri?authorId=55193803000

  2. ORCID. (n.d.). ORCID record: Alesia Tietze, ORCID iD 0000-0002-9281-548X.
    https://orcid.org/0000-0002-9281-548X

  3. Targeted sortase A inhibition by novel peptidomimetic antivirulents against staphylococcal infections

    https://pubmed.ncbi.nlm.nih.gov/41773879/

  4. DNA Scission by Non-Histidine Amino-Terminal Cu(II) and Ni(II) Binding-Like Peptides

    https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.70397

Rui Xiao | Molecular Genetics | Editorial Board Member

Published on by Global Genetics Award

Prof. Rui Xiao | Molecular Genetics | Editorial Board Member

Inner Mongolia Medical University | China

Rui Xiao is a Professor and Director of the Key Laboratory of Molecular Pathology at Inner Mongolia Medical University, China. With a Ph.D. in Animal Biotechnology from Konkuk University, South Korea, he has built a distinguished academic career focusing on gene functions and molecular mechanisms of major diseases. He has led over 30 funded research projects and published more than 100 scientific papers, along with contributing to books and holding multiple patents. Professor Xiao actively serves in several scientific societies and as an expert reviewer for national programs. His contributions have earned him numerous awards and recognitions, highlighting his impact in biomedical research and education.

Citation Metrics (Scopus)

300
200
100
10
0

Citations
165

Documents
23

h-index
6

Citations

Documents

h-index


View Scopus Profile
 View Orcid Profile

Featured Publications

Helala AlShehri | Cancer Genetics | Research Excellence Award

Published on by Global Genetics Award

Assist. Prof. Dr. Helala AlShehri | Cancer Genetics | Research Excellence Award

Jubail Industrial College | Saudi Arabia

Assist. Prof. Dr. Helala Mohammad AlShehri is an Assistant Professor of Computer Science and Deputy for Planning and Development at Jubail Industrial College, Saudi Arabia. She earned her PhD in Computer Science from King Saud University and brings together strong academic leadership with advanced research expertise in artificial intelligence and deep learning. Dr. AlShehri has held several senior administrative roles, including department chair and head of student and academic affairs, contributing significantly to institutional planning, quality assurance, and academic accreditation. Her research focuses on AI-driven medical image analysis, particularly histopathological image classification for cancer diagnosis, explainable AI, and computer-aided decision support. She has published nine peer-reviewed articles in SCI- and Scopus-indexed journals, with over 140 citations. Dr. AlShehri actively collaborates with national and international researchers and serves as a peer reviewer for leading AI and medical imaging journals.

Citation Metrics (Scopus)

1000
100
10
5
0

Citations
97

Documents
6

h-index
5

Citations

Documents

h-index


View Scopus Profile
 View Orcid Profile View Google Scholar Profile

Featured Publications

Dong MA | Epigenetics | Research Excellence Award

Published on by Global Genetics Award

Prof. Dong MA | Epigenetics | Research Excellence Award

Hebei Medical University | China

Prof. DONG MA, Ph.D., is a Professor and doctoral supervisor in the Department of Biochemistry and Molecular Biology at Hebei Medical University, where he conducts influential research in cardiovascular biology within the Key Laboratory of Neural and Vascular Biology, Ministry of Education, in Shijiazhuang, China. A Young Fellow of the American Heart Association (AHA), he serves as the principal investigator for three National Natural Science Foundation of China (NSFC)-funded projects, underscoring his leadership and innovation in cardiovascular research. Dr. Ma has published more than 20 high-impact papers in renowned international journals such as Circulation Research, PLOS Biology, Advanced Science, Cardiovascular Research, Redox Biology, and Frontiers in Cardiovascular Medicine.

Profiles: Scopus

Featured Publications

"Inhibition of CDK5 signaling mediated inflammation in macrophages promotes cutaneous wound healing", Prof. Dong MA., 2025

"A STAT1-GBP3-STING positive feedback loop governs inflammation, oxidative stress, and DNA damage to trigger acute aortic dissection", Prof. Dong MA., 2025

"Short-term Prognosis of Acute Stanford A Aortic Dissection in Young and Middle-aged Patients Treated with a Hybrid Surgery Versus Sun's Procedure", Prof. Dong MA., 2025

"The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral,Non-Alcoholic Hepatocellular Carcinoma:a Retrospective Cohort Study",Prof. Dong MA., 2025

Nasrin Samadyar | Cancer Genetics | Research Excellence Award

Published on by Global Genetics Award

Dr. Nasrin Samadyar | Cancer Genetics | Research Excellence Award

Kermanshah University of Technology, Kermanshah | Iran

Dr. Nasrin Samadyar, born on 17 June 1989 in Karaj, Alborz Province, Iran, is an Iranian applied mathematician specializing in numerical analysis, stochastic differential equations, and meshfree computational methods. She earned her BSc in Applied Mathematics from Kharazmi University, followed by an MSc from Amirkabir University of Technology and a PhD in Applied Mathematics (Numerical Analysis) from Malayer University, where her doctoral research focused on meshfree radial basis function methods for solving stochastic integral equations. She later completed a postdoctoral fellowship in Mathematics at Alzahra University, concentrating on numerical solutions of stochastic differential and partial differential equations. A dedicated educator, she has taught courses such as Numerical Analysis, Linear Optimization, Calculus, and Numerical Linear Algebra. Samadyar has authored numerous high-impact journal publications spanning stochastic integral equations, fractional models, operational matrix methods, wavelet techniques, and meshless approaches, contributing significantly to computational mathematics. She also serves as a reviewer for leading international journals, including the International Journal of Biomathematics, Journal of Computational and Applied Mathematics, Applied Mathematics and Computation, and Soft Computing. A member of Iran's National Elites Foundation, she has supervised graduate research on numerical and stochastic equation-solving techniques and participated in advanced mathematical projects, including implicit meshless methods for fractional stochastic Tricomi-type equations. Proficient in MATLAB, MAPLE, MATHEMATICA, LaTeX, and C++, Samadyar continues to advance research in applied and stochastic mathematics through rigorous analysis, innovative numerical schemes, and interdisciplinary applications.

Profiles: Scopus | Google Scholar

Featured Publications

"A new scheme for solving nonlinear Stratonovich Volterra integral equations via Bernoulli’s approximation, Appl", F. Mirzaee, N. Samadyar, S.F. Hosseini., 2025

"Euler polynomial solutions of nonlinear stochastic Ito-Volterra integral equations, J. Comput. Appl",F. Mirzaee, N. Samadyar, S.F. Hosseini., 2025

"Application of orthonormal Bernstein polynomials to construct a efficient scheme for solving fractional stochastic integro-differential equation, Optik Int. J. Light Electron Opt", F. Mirzaee, N. Samadyar., 2025

"Numerical solution of nonlinear stochastic Ito-Volterra integral equations driven by fractional Brownian motion, Math. Meth. Appl",F. Mirzaee, N. Samadyar., 2025

Xinghua Pan | Next-Generation Sequencing | Research Excellence Award

Published on by Global Genetics Award

Prof. Xinghua Pan | Next-Generation Sequencing | Research Excellence Award

Macau University of Science and Technology | China

Prof. Xinghua (Victor) Pan, PhD, MD, is a distinguished scholar in single-cell technology, genome medicine, cancer biology, regenerative medicine, and multi-omics bioinformatics, currently serving as a Professor at the Precision Regenerative Medicine Research Centre (PRMRC) in the Medical Science Division of Macau University of Science and Technology (MUST), with a secondary affiliation at the State Key Laboratory of Quality Research in Chinese Medicine. A doctoral supervisor in Biomedical Science and Pharmacy programs at MUST, Dr. Pan previously served as Chairman and Professor of Biochemistry and Molecular Biology at Southern Medical University (SMU), where he founded and led the Guangdong Provincial Key Laboratory of Single Cell Technology and Application and held multiple adjunct roles across major hospitals, universities, and national laboratories. With a career spanning Yale University—where he advanced from Associate Research Scientist to Research Scientist and PI-and leadership positions in molecular genomics companies, Dr. Pan brings decades of expertise shaped by rigorous training at Southern Medical University, Fudan University, CAMS & PUMC, and Yale University, complemented by international fellowships at Peking University, Melbourne University, the Ludwig Institute, and Cold Spring Harbor Laboratory. Renowned for pioneering single-cell sequencing innovations-including multiomics, copy-number, methylome, transcriptome, telomere, and multiplexing technologies-he has applied these breakthroughs to major biomedical challenges across cancer, stem cells, organoids, aging, infectious diseases, immunology, brain disorders, and precision medicine. Dr. Pan has authored over 160 publications in high-impact journals such as Nature, PNAS, Advanced Science, Nucleic Acids Research, and Nature Communications, accumulating more than 8,500 citations and an H-index of 40, alongside 15 issued patents in the U.S. and China. His work has been supported by national and international foundations including NSFC, NIH, NSF, MOST, and leading provincial and municipal programs. A dedicated educator who has trained over 60 researchers and taught nearly 10,000 students, he also serves as an Associate Editor of Precision Clinical Medicine and Monocytomics, reviewer for more than 30 top journals, and evaluator for major grant agencies and academic degree committees. As an organizer and keynote speaker at over 100 global conferences, including co-chairing the International Conference on Single Cell and Spatial Omics (TICSSO), Dr. Pan has also held leadership roles in multiple scientific societies and earned numerous accolades such as UICC and CSHL Scholarships, PolyGenomics Fellowship, VEBLEO Fellow, Nanjing Leading Talent, Guangzhou High-Level Talent, Ganpo Distinguished Professor, and the CastUSA Single Cell Genomics Pioneer Award, solidifying his global influence in single-cell biology and precision regenerative medicine.

Profiles: Scopus | Orcid

Featured Publications

"A medium throughput approach for single cell copy number variation sequencing towards efficient application in clinics", Guanchuan Lin; Caiming Chen; Mengchang Xu; Bin Peng; Zhanying Dong; Xuewen Zhou; Jinyu Gao; Jie Yu; Bei Jia; Chen Luo et al., 2025

"Causal effects of immune cell phenotypes on the risk of autoimmune liver diseases: a bidirectional two-sample Mendelian randomization study",Hongjie Zou; Xinghe Liang; Mengqi Luo; Xinghua Pan; De-Ke Jiang., 2025

"Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysis", Yulong Zhang; Yanfang Lu; Liyao Mai; Zebin Wen; Min Dai; Siwen Xu; Xianwei Lin; Yongjian Luo; Yinbin Qiu; Yuting Chen et al., 2025

"Transcriptomics-driven exploration of genetic variation and peptide discovery in the sea anemones Anthopleura midori and Actinia equina",Han Zhang; Xinghua Pan; Chen Weigang., 2025

Yong Xu | Cartilage Tissue | Best Researcher Award

Published on by Global Genetics Award

Dr. Yong Xu | Cartilage Tissue | Best Researcher Award

Tongji University | China

Author Profile

Scopus

✨ XU YONG: A PIONEER IN TUMOR TREATMENT AND TISSUE REPAIR ✨

🎓 EARLY ACADEMIC PURSUITS

Xu Yong was born on May 29, 1991, in Fuzhou, Jiangxi, and pursued a career in medicine from an early age. He embarked on his academic journey at Tongji University School of Medicine, where he obtained his Bachelor of Clinical Medicine (2010-2015). With a keen interest in thoracic surgery and tissue engineering, he continued his education at Shanghai Pulmonary Hospital, earning a Master's Degree in Thoracic Surgery (2015-2018). His academic dedication led him to pursue a Ph.D. in Thoracic Surgery (2018-2021) at the same institution, where he developed expertise in tumor treatment and tissue repair.

🌟 PROFESSIONAL ENDEAVORS

Following his Ph.D., Xu Yong joined Shanghai Pulmonary Hospital as a Resident Physician (2021-2024), where he honed his clinical skills in thoracic surgery and tissue engineering. In August 2024, he transitioned to a research-focused role as a Special Associate Researcher at the Nuclear Industry 416 Hospital, Provincial Clinical Medical Research Center. His work in this position is instrumental in advancing innovative solutions for tracheal tissue engineering and regenerative medicine.

⚖️ CONTRIBUTIONS AND RESEARCH FOCUS ON CARTILAGE TISSUE

Xu Yong’s research primarily revolves around tissue engineering for cartilage regeneration, with a strong emphasis on functional tracheal reconstruction. His groundbreaking work introduced the "ring strategy", which enables the construction of bionic tracheal tissue with an alternating cartilage ring-connective tissue ring arrangement. This strategy successfully demonstrated long-term functional reconstruction of long-segment tracheal defects in rabbit models.

⚛️ MAJOR RESEARCH PROJECTS

Xu Yong has been the Principal Investigator (PI) in multiple prestigious projects, including:

  • Shanghai Science and Technology Rising Star Project (2024-2027): Focused on high-bionic tracheal tissue engineering (400,000 RMB).
  • Youth Talent Support Project (2023-2025): Dedicated to tracheal tissue engineering (300,000 RMB).
  • National Natural Science Foundation of China (2024-2026): Developing simulated tracheal tissue for large animal models (300,000 RMB).
  • Shanghai Natural Science Foundation (2022-2025): Advancing the construction of bioengineered trachea (200,000 RMB).

Additionally, he is a key participant in a major project funded by the National Natural Science Foundation of China (2,150,000 RMB), focusing on the precise matching of multiple cell types for bionic construction of long-segment trachea.

✨ IMPACT AND INFLUENCE

Xu Yong’s contributions have significantly influenced the field of tissue engineering and regenerative medicine, particularly in tracheal defect repair. His innovative biomimetic tracheal tissue construction has paved the way for improved clinical applications in treating long-segment tracheal defects. His research bridges the gap between basic science and clinical translation, offering promising therapeutic solutions for thoracic surgery.

🏆 ACADEMIC CITATIONS AND PUBLICATIONS

Xu Yong has an impressive publication record, contributing to over 30 SCI papers with a cumulative impact factor exceeding 300. His key achievements include:

  • 20 papers as first/co-first author
  • 14 papers as corresponding/co-corresponding author
  • 15 papers with an impact factor greater than 10
  • Highest single impact factor: 27.4

Notable journals where his research has been published:

  • Advanced Materials (ADV MATER)
  • Advanced Functional Materials (Adv. Funct. Mater.)
  • Advanced Science (Adv Sci.)
  • Composites Part B: Engineering (COMPOS PART B-ENG)
  • International Journal of Bioprinting (INT J BIOPRINTING)

Additionally, he holds over 10 patents related to tissue engineering and regenerative medicine.

🎬 LEGACY AND FUTURE CONTRIBUTIONS

Xu Yong’s pioneering efforts in tracheal tissue engineering and tumor treatment have established a new benchmark in the field. His ring strategy has set the foundation for future research in biomimetic tracheal reconstruction. Moving forward, he aims to:

  • Advance clinical translation of biomimetic tracheal tissue into human trials.
  • Explore novel biomaterials and tissue engineering scaffolds.
  • Collaborate on interdisciplinary projects integrating AI-driven biomaterial development.

His contributions will continue to shape the future of thoracic surgery, offering lifesaving solutions for patients with severe tracheal defects.

✨ CONCLUSION

Xu Yong is a trailblazer in regenerative medicine and thoracic surgery, whose dedication to tissue engineering and tracheal reconstruction has the potential to revolutionize the field. With a solid foundation in research, clinical expertise, and a vision for innovation, he is poised to make lasting contributions to modern medicine.

📑 NOTABLE PUBLICATIONS 

"Cartilage structure-inspired nanofiber-hydrogel composite with robust proliferation and stable chondral lineage-specific differentiation function to orchestrate cartilage regeneration for artificial tracheal construction" 

  • Authors: Y., Li, Yaqiang , X., Xun, Xiaowei , L., Duan, Liang , Y., Xu, Yong , H., Xia, Huitang
  • Journal: Bioactive Materials
  • Year: 2025

"Polydopamine-loaded microneedles for sequential tumor ablation and osteochondral regeneration" 

  • Authors: B., Lin, Bin , Y., Xu, Yong , B., Liang, Bing
  • Journal: Materials Letters
  • Year: 2025

"Copper hydrogen phosphate nanosheets functionalized hydrogel with tissue adhesive, antibacterial, and angiogenic capabilities for tracheal mucosal regeneration" 

  • Authors: P., Wang, Pengli , E., Gao, Erji , T., Wang, Tao , C., Yang, Chen , L., Duan, Liang
  • Journal: Journal of Nanobiotechnology
  • Year: 2024

"3D printing of Ceffe-infused scaffolds for tailored nipple-like cartilage development" 

  • Authors: J., Ding, Jinghao , C., Wei, Chuanzhi , Y., Xu, Yong , W., Dai, Wufei , R., Chen, Ru
  • Journal: BMC Biotechnology
  • Year: 2024

"Injectable and self-healing sulfated hyaluronic acid/gelatin hydrogel as dual drug delivery system for circumferential tracheal repair" 

  • Authors: Y., Yang, Yayan , X., Zhu, Xinsheng , X., Liu, Xuezhe , N., Song, Nan , Q., Feng, Qian
  • Journal: International Journal of Biological Macromolecules
  • Year: 2024